#United States #Class Action #Tracleer #Bosentan #Maryland

Overview of the Class Action Lawsuit for Tracleer and Bosentan

The law firms Cohen Milstein Sellers & Toll PLLC and Hagens Berman Sobol Shapiro LLP have initiated a class action lawsuit concerning the branded medications, Tracleer and Bosentan. This case is of significant importance for individuals and organizations that have reimbursed for these drugs, as it may affect their legal rights and financial claims.

The Lawsuit's Background

This class action is currently pending in the United States District Court for the District of Maryland. The plaintiff alleges that several pharmaceutical companies, including Actelion Pharmaceuticals Ltd., Actelion Pharmaceuticals US, Inc., and Janssen Research & Development, LLC, have engaged in anti-competitive practices. Specifically, the suit claims that these companies unlawfully delayed the availability of cheaper generic versions of Tracleer, which is believed to have resulted in increased costs for consumers—those who paid for or reimbursed these drugs.

The defendants deny any wrongdoing in this matter.

Court Certification and Trial Details

The lawsuit has gained the court's attention, and it has been certified as a class action. The court denied a recent motion from the defendants to dismiss the case, indicating the strength of the plaintiffs' claims. A trial has been scheduled to take place from March 2, 2026, to April 9, 2026.

Your Rights and Options

Individuals and entities who believe they may be impacted by this lawsuit face a crucial decision:

• - Do Nothing: By opting not to take any action, affected parties may still be eligible to receive compensation or benefits resulting from the trial or any potential settlement. However, they would be legally bound by the trial's outcome and waive their right to sue the defendants independently on these claims.
• - Request Exclusion: Individuals also have the option to exclude themselves from the class action. This must be done by December 23, 2024. Exclusion means that while they would forfeit any potential compensation from the trial or settlement, they would retain the right to pursue separate legal action against the defendants concerning the same claims.

Who is Affected?

The class action consists of entities that have reimbursed or paid for Tracleer and Bosentan on behalf of their members, employees, or beneficiaries. Essential details include:

• - Eligibility includes a wide array of individuals and organizations that purchased these medications in numerous states and territories.
• - The class encompasses consumers who did not purchase the medications for resale from December 29, 2015, to September 6, 2024.
• - It excludes defendants and their affiliates, as well as federal and state governmental entities.

To determine if you qualify as a class member, more information is available at www.TracleerLitigation.com.

Additional Information

For those seeking more information on the class action or their rights, the official website provides resources, updates, and includes a contact number (1-877-354-3839). It is crucial for individuals involved to stay informed about any amendments or updates regarding the deadlines or proceedings of the court.

This class action not only highlights potential issues regarding pharmaceutical pricing but also emphasizes consumer rights in the healthcare sector. As the trial date approaches, all parties involved must review their options carefully to ensure that their rights are adequately protected.